The prospects for using the genetically engineered surface antigen of the hepatitis B virus (HBsAg) expressed by recombinant poxvirus strains as the basis for vaccines against hepatitis B

The use of a recombinant poxvirus (RPV) strain, expressing HBsAg in the process of reproduction in different bioreactor systems under stationary and bioreactor conditions of cultivation, made it possible to obtain highly purified HBsAg. The identity and purity of HBsAg was confirmed by the analysis of its amino acid composition, SDS electrophoresis in polyacrylamide gel, electron microscopy and high-performance liquid chromatography. Good prospects of the use of RPV-expressed gene engineering HBsAg as the basis vaccines against hepatitis B was demonstrated in 10 experimental batches of vaccine. All batches of the preparation had pronounced immunogenicity and were safe and nontoxic in animal experiments. The ID50 of experimental batches did not exceed 211 ng/ml, which, according to the data of comparative experiments, was lower than, or equal to, corresponding values of analogous foreign commercial preparations, based on plasma or yeast HBsAg.     

Services and applications: requirements and realizations in theUMTS era

The ACTS program is moving the results of the R&D of the parent RACE program nearer to realization through technology and user trials. Particularly in the mobile domain of ACTS, several projects have been investigating the user dimension in the context of the third-generation Universal Mobile Telecommunications Service. Results so far suggest many opportunities to broaden participation, exploit the inherent benefits of the mobile environment, and take advantage of the enormous improvements in wireless communications to realize the potential of global multimedia mobility. This article considers the needs of users for mobile multimedia applications and the consequences of those needs on the equipment, supporting services and teleservices, and communications bearers